Please use this identifier to cite or link to this item: http://hdl.handle.net/11455/91952
標題: 電化學沉積紫杉醇/氫氧基磷灰石複合塗層於鈦合金在生醫之應用
Electrochemical Deposition of Paclitaxel /HAp Composite on Ti Alloy for Biomedical Application
作者: 賴水濱
Shuei-Bin Lai
關鍵字: 紫杉醇
氫氧基磷灰石
鈦合金
Paclitaxel
Hydroxyapatite
Ti alloy
引用: 5. References [1] Ahmedin Jemal DVM, PhD, Freddie Bray PhD, Melissa M. Center MPH, Jacques Ferlay ME, Elizabeth Ward PhD and David Forman PhD, Global cancer statistics, 61 (2011) 69–90 [2] Bernard W. Stewart and Christopher P. Wild , World Cancer Report 2014 [3] National Cancer Institute, Updated: February 9 , 2015 http://www.cancer.gov/about-cancer/what-is-cancer [4] Lisa Brannon-Peppas, and James O. Blanchette, Nanoparticle and targeted systems for cancer therapy, Advanced drug delivery reviews, 64 (2012) 206–212. [5] Jeffrey K Mills, and David Needham, Targeted drug delivery, Expert Opinion on Therapeutic Patents, 9 (1999) 1499-1513 [6] Chemocare.com, Taxol, 2002 - 2015 http://chemocare.com/chemotherapy/drug-info/Taxol.aspx [7] Si-Shen Feng, and Shu Chienc, Chemotherapeutic engineering: application and further development of chemical engineering principles for chemotherapy of cancer and other diseases , Chemical Engineering Science, 58 (2003) 4087–4114. [8] William L Huntera, Helen M Burta, Lindsay Machanc, Local delivery of chemotherapy: a supplement to existing cancer treatments: A case for surgical pastes and coated stents, Advanced Drug Delivery Reviews, 26 (1997) 199–207. [9] Saltzman, W. Mark, and Torchilin, Vladimir P. “Drug Delivery Systems.” AccessScience. McGraw-Hill Education, 2014, Web. [10] Arnold I. Freeman, and Eric Mayhew , Targeted drug delivery, Cancer, 56 (1986),573–583. [11] 'Paclitaxel'. The American Society of Health-System Pharmacists. Retrieved May 11, 2015. [12] Horwitz SB, Taxol (paclitaxel): mechanisms of action, Annals of Oncology , 5 (1994) S3-6. [13] KL Hennenfent, R Govindan, Novel formulations of taxanes: a review. Old wine in a new bottle? Annals of oncology, 17 ( 2006) 735-749. [14] Anil K Singla, Alka Garg, Deepika Aggarwal, Paclitaxel and its formulations, International Journal of Pharmaceutics, 235 (2002) 179–192 [15] H Gelderblom, J Verweij, K Nooter, A Sparreboom, Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation, European Journal of Cancer, 37 (2001) 1590–1598 [16] T.M. Allen, A. Chonn,Large unilamellar liposomes with low uptake into the reticuloendothelial system,FEBS Letters, 223 (1987) 42–46 [17] Robert C Scott, Deborah Crabbe, Barbara Krynska, Ramin Ansari, and Mohammad F Kiani,Aiming for the heart: targeted delivery of drugs to diseased cardiac,Expert Opinion on Drug Delivery, 5 (2008) 459-470 [18] Glen S. Kwon, Kazunori Kataoka,Block copolymer micelles as long-circulating drug vehicles,Advanced Drug Delivery Reviews, 16 (1995) 295–309 [19] U.S. Food and Drug Administration, TAXUS™ Express 2™ Paclitaxel-Eluting Coronary Stent System (Monorail and Over-the-Wire) - P030025, Updated 2004 http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cftopic/pma/pma.cfm?num=p030025 [20] Refat Jabara, MD, Nicolas Chronos, MD, FACC, Damian Conway, MSc, Warner Molema, PhD, Keith Robinson, PhD, FACC, Evaluation of a Novel Slow-Release Paclitaxel-Eluting Stent With a Bioabsorbable Polymeric Surface Coating, JACC: Cardiovascular Interventions, 1 (2008) 81–87 [21] Alan W. Heldman, MD; Linda Cheng, PhD; G. Mark Jenkins, MD; Phillip F. Heller, PhD; Dong-Woon Kim, MD; Melvin Ware Jr, LAT; Cynthia Nater, BS; Ralph H. Hruban, MD; Banafsheh Rezai, MD; Benjamin S. Abella, MD; Katherine E. Bunge, MD; James L. Kinsella, PhD; Steven J. Sollott, MD; Edward G. Lakatta, MD; Jeffrey A. Brinker, MD; William L. Hunter, MD; Jeffrey P. Froehlich, MD, Paclitaxel Stent Coating Inhibits Neointimal Hyperplasia at 4 Weeks in a Porcine Model of Coronary Restenosis, Circulation, 103 (2001) 2289-2295 [22] Kenji Watanabe, Yuki Nishio, Rie Makiura, Atsushi Nakahira, Chie Kojima, Paclitaxel-loaded hydroxyapatite/collagen hybrid gels as drug delivery systems for metastatic cancer cells, International Journal of Pharmaceutics, 446 (2013) 81–86 [23] Tetsuya Abe, M.D., Masataka Sakane, M.D., Ph.D., Toshiyuki Ikoma, Ph.D., Mihoko Kobayashi, B.S., Satoshi Nakamura, Ph.D., and Naoyuki Ochiai, M.D., Ph.D., Intraosseous delivery of paclitaxel-loaded hydroxyapatitealginate composite beads delaying paralysis caused by metastatic spine cancer in rats, Journal of Neurosurgery: Spine, 9 ( 2008)502-510 [24] G. Devanand Venkatasubbu, , S. Ramasamy, G.S. Avadhani, , V. Ramakrishnan , J. Kumar, Surface modification and paclitaxel drug delivery of folic acid modified polyethylene glycol functionalized hydroxyapatite nanoparticles, Powder Technology, 235 (2013) 437–442 [25] Chi-Chuan Yang, Chien-Chung Lin and Shiow-Kang Yen,Electrochemical deposition of vancomycin/chitosan composite on Ti alloy, The Electrochemical Society, 158 (2011)152-158 [26] Chi-Chuan Yanga, Chien-Chung Lin, Jiunn-Wang Liao, Shiow-Kang Yen, Vancomycin–chitosan composite deposited on post porous hydroxyapatite coated Ti6Al4V implant for drug controlled release, Materials Science and Engineering: C, 33 (2013) 2203–2212 [27] SK Yen and CM Lin, Cathodic reactions of electrolytic hydroxyapatite coating on pure titanium, Materials chemistry and physics, 77 (2003) 70-76 [28] International Organization for Standardization, ISO 10995-5: Biological evaluation of medical devices Part 5: Tests for in vitro cytotoxicity : in vitro methods, (2009) [29] R.M.; Bassler, G.C.; and Morrill, T.C., Spectrometric Identification of Organic Compounds. 4th ed. New York: John Wiley and Sons, (1981)
摘要: With the average life expectancy getting longer and life habits changing, cancer is becoming one of the leading causes of death. In order to reduce the side effects of chemotherapy, many studies about the target treatment have been investigated recently. In this study, Paclitaxel, the drug for cancer treatment are electrochemically deposited on Ti alloy which could be applied to vascular stents for the tumor treatment by sustaining release of drug to achieve the apoptosis of cancer or the prevention of cancer metastasis. In the experiment, cathodic polarization tests coupled with electrochemical reactions were analyzed to speculate the deposition mechanism, and field emission scanning electron microscope (FESEM), focused ion beam (FIB) system and Fourier transform infrared spectroscopy (FTIR) to observe surface morphology and analyze constituent elements. A spectrophotometer (UV visible spectrometer) was used to measure drug loading and release. Finally, MTT Assay was carried out to analyze cell viability for drug efficacy. It is concluded that paclitaxel can be successfully deposited on the titanium alloy by electrochemical method and the post hydroxyapatite coated specimen with high porosity can enhance the drug loading from 395 to 572 μg /cm2 and reveal the more complete drug release.
隨著人類平均壽命越來越長以及生活習慣的改變,癌症逐漸成為死亡主要原因之一。為了減少化學療法帶來的副作用,近年來有許多關於標靶治療的研究。本研究將用於癌症治療的藥物紫杉醇(Paclitaxel)和氫氧基磷灰石(Hydroxyapatite) 複合沉積於鈦合金(Ti6Al4V)上,企圖應用於血管支架作為腫瘤之治療,藉由藥物釋放使癌細胞凋亡,並阻止癌細胞轉移。在實驗中利用陰極極化法檢視電化學沉積機制,並以場發射式掃描電子顯微鏡 (FESEM)、傅立葉紅外線光譜儀 (FTIR)、多功能聚焦離子束系統(FIB)進行表面形貌觀察與元素分析,再以分光光度計(UV visible spectrometer)量測載藥量和釋放曲線,最後以細胞存活率分析(MTT Assay)檢測藥效。結果顯示紫杉醇能成功地藉由電化學方法沉積於鈦合金上,若先沉積多孔形貌的氫氧基磷灰石(Hydroxyapatite)更可提高紫杉醇載藥量至572 μg /cm2並呈現更完整的藥量釋放。
URI: http://hdl.handle.net/11455/91952
其他識別: U0005-1507201515455400
文章公開時間: 10000-01-01
Appears in Collections:材料科學與工程學系

文件中的檔案:

取得全文請前往華藝線上圖書館



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.